THERAPY DOSSIER · th-5d6fd2befb0d

Genetic or pharmacological inhibition of macrophage colony-stimulating factor (CSF-1) signalling, and macrophage/dendritic cell depletion

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04301778 ↗PHASE2completed

Phase 2 durvalumab with CSF-1R inhibitor SNDX-6352 after embolization in intrahepatic cholangiocarcinoma

Unresectable Intrahepatic Cholangiocarcinoma

Enrolment: 5 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23143303 ↗2012Reported harm

CSF-1 signaling mediates recovery from acute kidney injury.

MouseIschaemia-reperfusionRenalC57BL/6 and transgenic micemaleMacrophage and dendritic cell depletion applied during the recovery phase after…

Model: Acute kidney injury induced by renal ischaemia/reperfusion, and a diphtheria toxin-induced model of selective proximal tubule injury

Depleting macrophages and dendritic cells or blocking CSF-1 signalling increased functional and histological injury, reduced M2 polarisation and delayed recovery, indicating that CSF-1-driven expansion of resident renal macrophages is required for tubule regeneration.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…